A Complete Response Letter (CRL) from the FDA due to manufacturing issues can destroy a biotech. CEO Ron Cooper warns leaders to invest heavily in Chemistry, Manufacturing, and Controls (CMC) early, even when the cost exceeds the clinical trial spend. This early investment in professionalizing CMC is critical to de-risk the company's future.

For gene editing to achieve its potential, companies must solve an economic problem, not just a scientific one. The key is developing a manufacturing system that dramatically lowers costs, making one-time cures for the "long tail" of rare mutations financially viable and accessible.

Failing to conduct comprehensive screening for strain selection and media development at the project's start creates issues that become significantly more difficult and expensive to resolve later. Small, early-stage problems can derail downstream processing and scale-up efforts entirely.

Neon Bio is pioneering a radical new form of drug manufacturing by genetically engineering chickens to produce therapeutic proteins in their eggs. This approach harnesses the chicken's natural efficiency as a 'protein factory' to create complex drugs, potentially making expensive treatments like Humira significantly more accessible.

A significant portion of biotech's high costs stems from its "artisanal" nature, where each company develops bespoke digital workflows and data structures. This inefficiency arises because startups are often structured for acquisition after a single clinical success, not for long-term, scalable operations.

Unlike a drug that can be synthesized to a chemical standard, most vaccines are living biological products. This means the entire manufacturing process must be perfectly managed and cannot be altered without re-validation. This biological complexity makes production far more difficult and expensive than typical pharmaceuticals.

Despite scientific breakthroughs and better technology, the cost per approved drug has steadily increased over the last 60 years. This phenomenon, the reverse of Moore's Law, is called Eroom's Law and highlights a fundamental productivity problem in the biopharma industry, with costs approaching $1B+ per successful drug.

The lack of new drugs for pre-term babies is a market failure. For three decades, progress has been crippled by a dual challenge: venture capital funds avoiding pediatric studies and regulatory agencies lacking recent experience in evaluating neonatal treatments, creating a vicious cycle of stagnation.

CEO Marc Salzberg clarifies that for their recombinant protein, the difficulty was not in the manufacturing itself but in designing the complex upstream process, purification, and analytics. This innovation became a core asset and "claim to fame," allowing them to transfer a well-defined process to a capable CDMO for scaling.